BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Neonc Technologies\, Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Neonc Technologies\, Inc.'s drugs
  run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05023018-10951@assetmemo.bio
DTSTAMP:20261121T005643Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:NEO100: Phase 2 readout est. (NCT05023018)
DESCRIPTION:NEO100\, phase 2.\nStudy: NEO100 and High-Grade Meningioma\nEst
 imated primary completion: 30 December 2026. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/neo100#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT05023018
URL:https://assetmemo.bio/drug/neo100#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06047379-2638@assetmemo.bio
DTSTAMP:20261121T005643Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:NEO212: Phase 1/2 readout est. (NCT06047379)
DESCRIPTION:NEO212\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Safety
  and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant\, Glioblas
 toma IDH-wildtype or Brain Metastasis\nEstimated primary completion: 28 Fe
 bruary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/neo212#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06047
 379
URL:https://assetmemo.bio/drug/neo212#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
